[go: up one dir, main page]

WO2023195954A1 - Comprimé pelliculé comprenant une dispersion solide de sélexi̇pag - Google Patents

Comprimé pelliculé comprenant une dispersion solide de sélexi̇pag Download PDF

Info

Publication number
WO2023195954A1
WO2023195954A1 PCT/TR2023/050303 TR2023050303W WO2023195954A1 WO 2023195954 A1 WO2023195954 A1 WO 2023195954A1 TR 2023050303 W TR2023050303 W TR 2023050303W WO 2023195954 A1 WO2023195954 A1 WO 2023195954A1
Authority
WO
WIPO (PCT)
Prior art keywords
film coated
coated tablet
selexipag
cellulose
solid dispersion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2023/050303
Other languages
English (en)
Inventor
Fatih Sunel
Fadime Bilgehan ATAK
Nur PEHLIVAN AKALIN
Guldeniz TUNC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2022/005274 external-priority patent/TR2022005274A1/tr
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of WO2023195954A1 publication Critical patent/WO2023195954A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Definitions

  • the present invention relates to a film coated tablet comprising a solid dispersion of selexipag or crystalline polymorph thereof, wherein the solid dispersion further comprising at least one binder and solvent. Furthermore, the tablet is obtained using an effective process.
  • Selexipag is prostacyclin receptor agonist that causes vasodilation in pulmonary vasculature and is used in the therapy of pulmonary arterial hypertension (PAH).
  • Selexipag also known as 2-(4-((5,6- diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide can be represented by the following chemical structure according to Formula I:
  • each round film-coated tablet for oral administration contains 200, 400, 600, 800, 1000, 1200, 1400, or 1600 mcg of Selexipag.
  • the Uptravi® film-coated tablet is a standard immediate-release tablet that contains D-mannitol, corn starch, low substituted hydroxypropylcellulose, hydroxypropylcellulose, and magnesium stearate.
  • the tablets are film coated with a coating material containing hypromellose, propylene glycol, titanium dioxide, carnauba wax along with mixtures of iron oxide red, iron oxide yellow or iron oxide black.
  • Selexipag is considered to be a BCS (Biopharmaceutics Classification System) Class II drug, i.e. having high permeability and low solubility.
  • BCS Biopharmaceutics Classification System
  • EP3481807 discloses novel crystalline forms of selexipag and its process for the preparation thereof.
  • WO 2017/029594 describes the preparation of amorphous selexipag by dissolving the drug in a suitable solvent, e.g. acetone, and removing the solvent by, e.g., evaporation, spray-drying or freeze- drying.
  • the main object of the present invention is to provide a film coated tablet comprises a solid dispersion of selexipag or crystalline polymorph thereof with having the desired level of dissolution rate and high stability and excellent physicochemical properties, such as flowability, compressibility, homogeneity, and content uniformity which overcomes the above-described problems in the prior art and have additive advantages over them.
  • Another object of the present invention is to provide a process for preparing a film coated tablet composition comprising selexipag or crystalline polymorph thereof.
  • the process is a simple, rapid, cost effective, time-saving, and industrially convenient method.
  • selexipag or crystalline polymorph thereof is used small proportion that can lead to considerable problems during the manufacture of the composition with regard to the uniformity of the content of active agent in the individual composition units. Because of problems uniformity of the content, the active substance may interact with several excipients. It reflects that content uniformity play important role in the dissolution of the drug.
  • a film coated tablet comprises a solid dispersion of selexipag or crystalline polymorph thereof, wherein the solid dispersion further comprising at least one binder and solvent.
  • Suitable solvents are selected from the group comprising pure water, dichloromethane, 0.1N HCI, methanol, ethanol, isopropyl alcohol, benzyl alcohol, propylene glycol, polyethylene glycol, glycerine, cyclomethicone, glycerine triacetate, diethylene glycol monoethyl ether or mixtures thereof.
  • the solvent is water or ethanol or methanol or dichloromethane.
  • Suitable binders are selected from the group comprising hydroxypropyl methyl cellulose, polyvinylpyrrolidone, sodium carboxymethyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol, pregelatinized starch, sodium alginate, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, polymethacrylates, methacrylate polymers, polysaccharides, carbomer, poloxamer, polyacrylamide, aluminium hydroxide, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
  • the binder is hydroxypropyl methyl cellulose.
  • HPMC hydroxypropyl methyl cellulose.
  • the amount of binder is between 1.0% and 8.0%, between 2.0% and 6.0% by weight of the total tablet.
  • the amount of selexipag or crystalline polymorph thereof is between 0.05% and 5.0%, preferably between 0.05% and 2.0% by weight of the total tablet.
  • selexipag is present in the form of amorph or form P or form 1 or form 3.
  • selexipag is present in the form of amorph.
  • selexipag is present in the form of form P. It provides a tablet with high yields and purity.
  • selexipag is present in the form of form 3.
  • the film coated tablet further comprises at least one pharmaceutically acceptable excipient selected from the group comprising fillers, disintegrants, lubricants or mixtures thereof.
  • Suitable fillers are selected from the group comprising corn starch, microcrystalline cellulose, lactose monohydrate, neutral pellets, calcium sulfate, cellulose, cellulose acetate, compressible sugar, ethylcellulose, fructose, glyceryl palmitostearate, lactitol, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, sodium alginate, sodium chloride, sorbitol, sucrose, sugar spheres, talc, tragacanth, trehalose, xylitol or mixtures thereof.
  • fillers are D-mannitol and corn starch.
  • D-mannitol and corn starch help to provide both the desired stability and excellent pharmacomechanic properties.
  • the amount of filler is between 70.0% and 95.0%, between 78.0% and 90.0% by weight of the total tablet.
  • the amount of D-mannitol is between 45.0% and 58.0%, between 50.0% and 56.0% by weight of the total tablet.
  • the amount of corn starch is between 25.0% and 45.0%, between 30.0% and 40.0% by weight of the total tablet.
  • Suitable disintegrants are selected from the group comprising low-substituted hydroxypropyl cellulose, croscarmellose sodium, crospovidone, carboxymethyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl starch, hydroxymethyl starch or mixtures thereof.
  • the disintegrant is low-substituted hydroxypropyl cellulose.
  • low-substituted hydroxypropyl cellulose has proven to offer substantial advantages as disintegrant because of its ability to turn low-soluble selexipag into fast-dissolving stable pellets. Also, its use in the specified range provided the desired dissolution profile.
  • the amount of low-substituted hydroxypropyl cellulose is between 2.0% and 10.0% by weight of the total tablet.
  • Suitable lubricants are selected from the group comprising magnesium stearate, calcium stearate, sodium stearyl fumarate, potassium stearate, stearic acid, sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols or mixtures thereof.
  • the lubricant is magnesium stearate.
  • the amount of lubricant is between 0.5% and 3.5% by weight of the total tablet.
  • the film coated tablet further comprises at least one coloring agent.
  • Suitable coloring agents are selected from the group comprising indigo carmin aluminum lake, ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), poncau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof. Coloring agent contributes positively to the shelf life of the product and so the desired stability.
  • FD&C Drug & Cosmetic
  • the film coated tablet comprises;
  • a solid dispersion comprising crystalline form-P, 1 or 3 or amorph of selexipag and hydroxypropyl methyl Cellulose E3 LV D-Mannitol
  • Magnesium stearate Magnesium stearate.
  • the film coated tablet comprises;
  • a solid dispersion comprising crystalline form-P or 3 or amorph of selexipag and hydroxypropyl methyl Cellulose E3 LV D-Mannitol
  • Magnesium stearate Magnesium stearate.
  • the film coated tablet is obtained by wet granulation using solvent with solid dispersion technique.
  • This solid dispersion technique provides the homogeneity and content uniformity of the active substance used in low amounts and the desired dissolution profile.
  • wet granulation with solid dispersion technique is preferred in terms of pharmacotechnical properties, such as flowability, compressibility and content uniformity of selexipag.
  • suitable solvent also provides the desired stability.
  • a process for preparing a film coated tablet comprising selexipag or crystalline polymorph thereof comprises the following steps: a) Dissolving hydroxypropyl methyl cellulose in solvent and adjusting pH and obtained a binder solution, b) Adding selexipag or crystalline polymorph thereof in the binder solution, and dissolving, and obtained a solid dispersion, c) Mixing low substituted hydroxypropyl cellulose and corn starch and then adding D-mannitol and mixing, d) Granulating the powder mixture at step (c) with the binder solution at step (b), and obtained wet granule, e) Sieving the wet granule and then drying, f) Adding magnesium stearate and then mixing, g) Compressing the mixture into tablets, h) Coating the tablets.
  • a process for preparing a film coated tablet comprising selexipag or crystalline polymorph thereof comprises the following steps: a) Dissolving hydroxypropyl methyl cellulose in solvent and adjusting pH and obtained a binder solution, b) Adding selexipag or crystalline polymorph thereof in the binder solution, and dissolving, and obtained a solid dispersion, c) Mixing low substituted hydroxypropyl cellulose and corn starch and then adding D-mannitol and mixing, d) Granulating the powder mixture at step (c) with the binder solution at step (b), and obtained wet granule, e) Sieving the wet granule and then drying, f) Adding at least one coloring agent and then mixing, g) Adding magnesium stearate and then mixing, h) Compressing the mixture into tablets, i) Coating the tablets.
  • Example 1 Example 2: A process for example 1 or 2; a) Dissolving hydroxypropyl methyl cellulose in solvent and adjusting pH and obtained a binder solution, b) Adding selexipag or crystalline polymorph thereof in the binder solution, and dissolving, and obtained a solid dispersion, c) Mixing low substituted hydroxypropyl cellulose and corn starch and then adding D-mannitol and mixing, d) Granulating the powder mixture at step (c) with the binder solution at step (b), and obtained wet granules, e) Sieving the wet granules and then drying, f) Adding magnesium stearate and then mixing, g) Compressing the mixture into tablets, h) Coating the tablets.
  • a process for example 3 a) Dissolving hydroxypropyl methyl cellulose in solvent and adjusting pH and obtained a binder solution, b) Adding selexipag or crystalline polymorph thereof in the binder solution, and dissolving, and obtained a solid dispersion, c) Mixing low substituted hydroxypropyl cellulose and corn starch and then adding D-mannitol and mixing, d) Granulating the powder mixture at step (c) with the binder solution at step (b), and obtained wet granule, e) Sieving the wet granule and then drying, f) Adding at least one coloring agent and then mixing, g) Adding magnesium stearate and then mixing, h) Compressing the mixture into tablets, i) Coating the tablets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un comprimé pelliculé comprenant une dispersion solide de sélexipag ou d'un polymorphe cristallin de celui-ci, la dispersion solide comprenant en outre au moins un liant et un solvant. En outre, le comprimé est obtenu à l'aide d'un processus efficace.
PCT/TR2023/050303 2022-04-05 2023-03-30 Comprimé pelliculé comprenant une dispersion solide de sélexi̇pag Ceased WO2023195954A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2022005274 2022-04-05
TR2022/005274 TR2022005274A1 (tr) 2022-04-05 Seleksi̇pag'in bi̇r kati di̇spersi̇yonunu i̇çeren bi̇r fi̇lm kapli tablet

Publications (1)

Publication Number Publication Date
WO2023195954A1 true WO2023195954A1 (fr) 2023-10-12

Family

ID=88243351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2023/050303 Ceased WO2023195954A1 (fr) 2022-04-05 2023-03-30 Comprimé pelliculé comprenant une dispersion solide de sélexi̇pag

Country Status (1)

Country Link
WO (1) WO2023195954A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025190465A1 (fr) * 2024-03-13 2025-09-18 Rontis Hellas S.A. Composition pharmaceutique stable contenant du sélexipag et son procédé de préparation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020255157A1 (fr) * 2019-06-20 2020-12-24 Aizant Drug Research Solutions Private Limited Forme posologique solide stable de sélexipag et son procédé de préparation
US20210069187A1 (en) * 2019-05-11 2021-03-11 RK Pharma Solutions LLC Stable pharmaceutical composition of Selexipag
WO2021078835A1 (fr) * 2019-10-23 2021-04-29 Actelion Pharmaceuticals Ltd Composition pharmaceutique comprenant du sélexipag

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069187A1 (en) * 2019-05-11 2021-03-11 RK Pharma Solutions LLC Stable pharmaceutical composition of Selexipag
WO2020255157A1 (fr) * 2019-06-20 2020-12-24 Aizant Drug Research Solutions Private Limited Forme posologique solide stable de sélexipag et son procédé de préparation
WO2021078835A1 (fr) * 2019-10-23 2021-04-29 Actelion Pharmaceuticals Ltd Composition pharmaceutique comprenant du sélexipag

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025190465A1 (fr) * 2024-03-13 2025-09-18 Rontis Hellas S.A. Composition pharmaceutique stable contenant du sélexipag et son procédé de préparation

Similar Documents

Publication Publication Date Title
US8709485B2 (en) Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
WO2023195955A1 (fr) Comprimé revêtu d'un film comprenant du sélexi̇pag et son procédé de préparation
TWI660748B (zh) 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
CA3206336A1 (fr) Comprime pellicule de film comprenant du teriflunomide
WO2023195953A1 (fr) Comprimé pelliculé comprenant du selexi̇pag
WO2023195957A1 (fr) Comprimé pelliculé comprenant du selexi̇pag traité par granulation humide
HK1245646A1 (zh) 口服给药用医药组合物
WO2023195954A1 (fr) Comprimé pelliculé comprenant une dispersion solide de sélexi̇pag
WO2023195956A1 (fr) Comprimé revêtu d'un film comprenant du sélexi̇pag et au moins une charge
EP4504195A1 (fr) Comprimé pelliculé comprenant du selexipag traité par granulation humide
WO2017037645A1 (fr) Formulations pharmaceutiques stables de tériflunomide
WO2022153330A1 (fr) Compositions pharmaceutiques comprenant de l'acalabrutinib
WO2024144679A2 (fr) Formulation en comprimé comprenant du selexi̇pag
TR2022005274A1 (tr) Seleksi̇pag'in bi̇r kati di̇spersi̇yonunu i̇çeren bi̇r fi̇lm kapli tablet
EP4393476A1 (fr) Formulation de comprimé comprenant du sélexipag
WO2024144726A1 (fr) Formulations comprenant du selexipag
TR2022005276A1 (tr) Seleksi̇pag ve en az bi̇r dolgu maddesi̇ i̇çeren bi̇r fi̇lm kapli tablet
WO2020055359A2 (fr) Forme posologique orale de tosylate de sorafénib
TR2022005275A2 (tr) Seleksi̇pag i̇çeren bi̇r fi̇lm kapli tablet ve bunun hazirlanma prosesi̇
TR2022005273A2 (tr) Seleksi̇pag i̇çeren bi̇r fi̇lm kapli tablet
TR2022005277A2 (tr) Yaş granülasyon i̇le i̇şlenmi̇ş seleksi̇pag i̇çeren bi̇r fi̇lm kapli tablet
WO2022162687A1 (fr) Compositions pharmaceutiques comprenant du nilotinib
EP4378455A1 (fr) Formulation pharmaceutique comprenant de l'empagliflozine
EP4393475A1 (fr) Formulations comprenant du sélexipag
EP4393474A1 (fr) Formulation comprenant du sélexipag

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23785125

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE